1'-[spiro{4H-3,1-6-methylbenzoxazine-4,4'-piperidine}-2-(1H)-one]carbamic acid tert-butyl ester | 364607-54-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 1'-[spiro{4H-3,1-6-methylbenzoxazine-4,4'-piperidine}-2-(1H)-one]carbamic acid tert-butyl ester
• 英文别名: tert-butyl 6-methyl-2-oxospiro[1H-3,1-benzoxazine-4,4'-piperidine]-1'-carboxylate
• CAS: 364607-54-5
• 化学式: C₁₈H₂₄N₂O₄
• 分子量: 332.4
• InChiKey: SIUMVXFLIYGVPL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  67.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1'-[spiro{4H-3,1-6-methylbenzoxazine-4,4'-piperidine}-2-(1H)-one]carbamic acid tert-butyl ester 在 盐酸 作用下， 以 乙醇 为溶剂， 反应 1.0h， 以95%的产率得到6-methylspiro{4H-3,1-benzoxazine-4,4'-piperidin}-2-(1H)-one hydrochloride
  参考文献：
  名称：

  CCR2:  Characterization of the Antagonist Binding Site from a Combined Receptor Modeling/Mutagenesis Approach

  摘要：

  We describe here a classical molecular modeling exercise that was carried out to provide a basis for the design of novel antagonist ligands of the CCR2 receptor. Using a theoretical model of the CCR2 receptor, docking studies were carried out to define plausible binding modes for the various known antagonist ligands, including our own series of indole piperidine compounds. On the basis of these results, a number of site-directed mutations (SDM) were designed that were intended to verify the proposed docking models. From these it was clear that further refinements would be necessary in the model. This was aided by the publication of a crystal structure of bovine enabled us to define ligand-docking hypotheses that were in complete agreement with the results of the SDM experiments.

  DOI：

  10.1021/jm030862l
• 作为产物：
  描述：

  N-叔丁氧羰基-4-哌啶酮 、 2-溴-4-甲基苯基氨基甲酸叔丁酯 在 甲基锂 、 叔丁基锂 、 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 反应 18.5h， 以52%的产率得到1'-[spiro{4H-3,1-6-methylbenzoxazine-4,4'-piperidine}-2-(1H)-one]carbamic acid tert-butyl ester
  参考文献：
  名称：

  CCR2:  Characterization of the Antagonist Binding Site from a Combined Receptor Modeling/Mutagenesis Approach

  摘要：

  We describe here a classical molecular modeling exercise that was carried out to provide a basis for the design of novel antagonist ligands of the CCR2 receptor. Using a theoretical model of the CCR2 receptor, docking studies were carried out to define plausible binding modes for the various known antagonist ligands, including our own series of indole piperidine compounds. On the basis of these results, a number of site-directed mutations (SDM) were designed that were intended to verify the proposed docking models. From these it was clear that further refinements would be necessary in the model. This was aided by the publication of a crystal structure of bovine enabled us to define ligand-docking hypotheses that were in complete agreement with the results of the SDM experiments.

  DOI：

  10.1021/jm030862l

文献信息

• CCR2:  Characterization of the Antagonist Binding Site from a Combined Receptor Modeling/Mutagenesis Approach
  作者：Theo A. Berkhout、Frank E. Blaney、Angela M. Bridges、David G. Cooper、Ian T. Forbes、Andrew D. Gribble、Pieter H. E. Groot、Adam Hardy、Robert J. Ife、Rejbinder Kaur、Kitty E. Moores、Helen Shillito、Jennifer Willetts、Jason Witherington

  DOI：10.1021/jm030862l

  日期：2003.9.1

  We describe here a classical molecular modeling exercise that was carried out to provide a basis for the design of novel antagonist ligands of the CCR2 receptor. Using a theoretical model of the CCR2 receptor, docking studies were carried out to define plausible binding modes for the various known antagonist ligands, including our own series of indole piperidine compounds. On the basis of these results, a number of site-directed mutations (SDM) were designed that were intended to verify the proposed docking models. From these it was clear that further refinements would be necessary in the model. This was aided by the publication of a crystal structure of bovine enabled us to define ligand-docking hypotheses that were in complete agreement with the results of the SDM experiments.